Published in Cancer Vaccine Week, September 5th, 2005
Revenue for the quarter and 6 months ended June 30, 2005, was $1.2 million and $3.1 million, respectively, compared to $1.9 million and $4.4 million for the same periods in 2004. Net loss for the quarter and 6 months ended June 30, 2005, was $1.7 million and $4.1 million, respectively, or $0.11 and $0.25 per basic and diluted share, respectively. This compares with a net loss of $0.9 million and $1.4 million for the same periods in 2004, or $0.06 and $0.09 per basic and diluted share, respectively. During the quarter ended June 30, 2005, cash and cash equivalents...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Vaccine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.